CoChat

Serotonin Transporter and Plasma Membrane Monoamine Transporter Are Necessary for the Antidepressant-Like Effects of Ketamine in Mice

Open access
Bowman, Melodi A., Vitela, Melissa, Clarke, Kyra M., Koek, Wouter, Daws, Lynette C. · 2020 · International Journal of Molecular Sciences

The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index, and 1 are not checked yet.

Abstract

Major depressive disorder is typically treated with selective serotonin reuptake inhibitors (SSRIs), however, SSRIs take approximately six weeks to produce therapeutic effects, if any. Not surprisingly, there has been great interest in findings that low doses of ketamine, a non-competitive N-methyl-D-aspartate (NMDA) receptor antagonist, produce rapid and long-lasting antidepressant effects. Preclinical studies show that the antidepressant-like effects of ketamine are dependent upon availability of serotonin, and that ketamine increases extracellular serotonin, yet the mechanism by which this occurs is unknown. Here we examined the role of the high-affinity, low-capacity serotonin transporter (SERT), and the plasma membrane monoamine transporter (PMAT), a low-affinity, high-capacity transporter for serotonin, as mechanisms contributing to ketamine’s ability to increase extracellular serotonin and produce antidepressant-like effects. Using high-speed chronoamperometry to measure real-time clearance of serotonin from CA3 region of hippocampus in vivo, we found ketamine robustly inhibited serotonin clearance in wild-type mice, an effect that was lost in mice constitutively lacking SERT or PMAT. As expected, in wild-type mice, ketamine produced antidepressant-like effects in the forced swim test. Mapping onto our neurochemical findings, the antidepressant-like effects of ketamine were lost in mice lacking SERT or PMAT. Future research is needed to understand how constitutive loss of either SERT or PMAT, and compensation that occurs in other systems, is sufficient to void ketamine of its ability to inhibit serotonin clearance and produce antidepressant-like effects. Taken together with existing literature, a critical role for serotonin, and its inhibition of uptake via SERT and PMAT, cannot be ruled out as important contributing factors to ketamine’s antidepressant mechanism of action. Combined with what is already known about ketamine’s action at NMDA receptors, these studies help lead the way to the development of drugs that lack ketamine’s abuse potential but have superior efficacy in treating depression.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21207581

Cites

80 of 81 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Isoflurane does not impact serotonin clearance at low concentrations. (A) Representative trace with signal parameters defined; (B) Serotonin signal amplitude did not change as a function of isoflurane percentage; (C) Serotonin clearance time (T20-T60) and (D) (T80) in seconds at varying concentrations of isoflurane (1.0–2.5%). There was no statistically significant difference in serotonin clearance time among the isoflurane concentrations. Circles represent individual mice. Data are mean ± S.E.M.
Figure 1 Isoflurane does not impact serotonin clearance at low concentrations. (A) Representative trace with signal parameters defined; (B) Serotonin signal amplitude did not change as a function of isoflurane percentage; (C) Serotonin clearance time (T20-T60) and (D) (T80) in seconds at varying concentrations of isoflurane (1.0–2.5%). There was no statistically significant difference in serotonin clearance time among the isoflurane concentrations. Circles represent individual mice. Data are mean ± S.E.M.CC BY · PubMed Central
Figure 2 Comparison of serotonin clearance among serotonin transporter (SERT) and plasma membrane monoamine transporter (PMAT) genotypes. (A) Representative traces of basal serotonin clearance in SERT+/+, SERT−/−, PMAT+/+, and PMAT−/− mice. (B) Basal serotonin signal amplitude, and (D) T80 clearance time did not differ significantly among genotypes. There was an effect of genotype in basal T20-T60 serotonin clearance time (C) where PMAT+/+ cleared serotonin more slowly than SERT+/+ mice (but see Figure 3). Welch’s one-way ANOVA with Tukey’s post-hoc comparisons. * p < 0.05. Circles represent individual mice. Data are mean ± S.E.M.
Figure 2 Comparison of serotonin clearance among serotonin transporter (SERT) and plasma membrane monoamine transporter (PMAT) genotypes. (A) Representative traces of basal serotonin clearance in SERT+/+, SERT−/−, PMAT+/+, and PMAT−/− mice. (B) Basal serotonin signal amplitude, and (D) T80 clearance time did not differ significantly among genotypes. There was an effect of genotype in basal T20-T60 serotonin clearance time (C) where PMAT+/+ cleared serotonin more slowly than SERT+/+ mice (but see Figure 3). Welch’s one-way ANOVA with Tukey’s post-hoc comparisons. * p < 0.05. Circles represent individual mice. Data are mean ± S.E.M.CC BY · PubMed Central
Figure 3 Serotonin clearance time (T20-T60 and T80) does not differ between PMAT+/+ and PMAT−/− mice, regardless of serotonin concentration. (A) There was no statistically significant difference between PMAT+/+ and PMAT−/− mice in serotonin clearance time (T20-T60 and T80) in CA3 of hippocampus at “low” concentration of serotonin (0.25 µM to 0.75 µM) or (B) “high” concentrations of serotonin (0.85 µM to 2.0 µM). (C) There was no statistically significant difference between PMAT+/+ and PMAT−/− mice in serotonin clearance time (T20-T60 and T80) in nucleus accumbens at “low” concentration of serotonin (0.25 µM to 0.75 µM) and (D) “high” concentrations of serotonin (0.85 µM to 2.0 µM). Note that the ordinates differ between CA3 region of hippocampus (panels A and B), and NAcc (panels C and D). Circles represent individual mice. Data are as mean ± S.E.M.
Figure 3 Serotonin clearance time (T20-T60 and T80) does not differ between PMAT+/+ and PMAT−/− mice, regardless of serotonin concentration. (A) There was no statistically significant difference between PMAT+/+ and PMAT−/− mice in serotonin clearance time (T20-T60 and T80) in CA3 of hippocampus at “low” concentration of serotonin (0.25 µM to 0.75 µM) or (B) “high” concentrations of serotonin (0.85 µM to 2.0 µM). (C) There was no statistically significant difference between PMAT+/+ and PMAT−/− mice in serotonin clearance time (T20-T60 and T80) in nucleus accumbens at “low” concentration of serotonin (0.25 µM to 0.75 µM) and (D) “high” concentrations of serotonin (0.85 µM to 2.0 µM). Note that the ordinates differ between CA3 region of hippocampus (panels A and B), and NAcc (panels C and D). Circles represent individual mice. Data are as mean ± S.E.M.CC BY · PubMed Central
Figure 4 Ketamine significantly inhibited serotonin clearance in wild-type mice, but not in mice lacking SERT or PMAT. (A) Representative oxidation currents produced by pressure-ejecting serotonin into CA3 region of hippocampus before (grey) and after (black) local application of ketamine. Traces are superimposed for ease of comparison. (B) Percent change in serotonin signal amplitude did not differ between treatments and across genotypes. Percent change in serotonin clearance time (C) T20-T60, and (D) T80 increased in wild-type mice, but was unchanged in SERT−/− and PMAT−/− mice. (E) Representative time course for serotonin clearance in a wild-type mouse following ketamine ejection. Note that pressure-ejection of ketamine did not perturb baseline oxidation current, indicating that ketamine did not evoke detectable release of endogenous serotonin. * p < 0.05 ** p < 0.01. Circles represent individual mice. Data are mean ± S.E.M.
Figure 4 Ketamine significantly inhibited serotonin clearance in wild-type mice, but not in mice lacking SERT or PMAT. (A) Representative oxidation currents produced by pressure-ejecting serotonin into CA3 region of hippocampus before (grey) and after (black) local application of ketamine. Traces are superimposed for ease of comparison. (B) Percent change in serotonin signal amplitude did not differ between treatments and across genotypes. Percent change in serotonin clearance time (C) T20-T60, and (D) T80 increased in wild-type mice, but was unchanged in SERT−/− and PMAT−/− mice. (E) Representative time course for serotonin clearance in a wild-type mouse following ketamine ejection. Note that pressure-ejection of ketamine did not perturb baseline oxidation current, indicating that ketamine did not evoke detectable release of endogenous serotonin. * p < 0.05 ** p < 0.01. Circles represent individual mice. Data are mean ± S.E.M.CC BY · PubMed Central
Figure 5 Ketamine lacks antidepressant-like effects in constitutive SERT or PMAT knockout mice. (A) Immobility time (s) in the tail suspension test and (B) Immobility time (s) in the forced swim test, in C57BL/6 mice given ketamine (3.2, 10, or 32 mg/kg) or saline. * p < 0.05 represents 32.0 mg/kg ketamine significantly different from saline. Tukey’s post-hoc test for multiple comparisons. (C) Immobility time in the FST after 32.0 mg/kg ketamine or saline administered one hour prior to testing in SERT+/+ or SERT−/− mice. * p < 0.05 represents 32.0 mg/kg ketamine significantly different from saline; Tukey’s post-hoc test for multiple comparisons. (D) Immobility time in the FST after 32.0 mg/kg ketamine or saline administered one hour prior to testing in PMAT+/+ or PMAT−/− mice. * p < 0.05 represents 32.0 mg/kg ketamine significantly different from saline. Tukey’s post-hoc test for multiple comparisons. Circles represent individual mice. Data are mean ± S.E.M.
Figure 5 Ketamine lacks antidepressant-like effects in constitutive SERT or PMAT knockout mice. (A) Immobility time (s) in the tail suspension test and (B) Immobility time (s) in the forced swim test, in C57BL/6 mice given ketamine (3.2, 10, or 32 mg/kg) or saline. * p < 0.05 represents 32.0 mg/kg ketamine significantly different from saline. Tukey’s post-hoc test for multiple comparisons. (C) Immobility time in the FST after 32.0 mg/kg ketamine or saline administered one hour prior to testing in SERT+/+ or SERT−/− mice. * p < 0.05 represents 32.0 mg/kg ketamine significantly different from saline; Tukey’s post-hoc test for multiple comparisons. (D) Immobility time in the FST after 32.0 mg/kg ketamine or saline administered one hour prior to testing in PMAT+/+ or PMAT−/− mice. * p < 0.05 represents 32.0 mg/kg ketamine significantly different from saline. Tukey’s post-hoc test for multiple comparisons. Circles represent individual mice. Data are mean ± S.E.M.CC BY · PubMed Central
Figure 6 Ketamine did not significantly impact locomotor activity of SERT+/+, SERT−/−, PMAT+/+, or PMAT−/− mice. (A) There was no significant difference in locomotor activity of SERT+/+ and SERT−/−, or (B) PMAT+/+ and PMAT−/− mice, when given ketamine or saline. Bar graphs show total number of beam breaks in the two-hour recording period. Panels on the right show beam breaks in 5 min bins as a function of time. Circles represent individual mice. Data are mean ± S.E.M.
Figure 6 Ketamine did not significantly impact locomotor activity of SERT+/+, SERT−/−, PMAT+/+, or PMAT−/− mice. (A) There was no significant difference in locomotor activity of SERT+/+ and SERT−/−, or (B) PMAT+/+ and PMAT−/− mice, when given ketamine or saline. Bar graphs show total number of beam breaks in the two-hour recording period. Panels on the right show beam breaks in 5 min bins as a function of time. Circles represent individual mice. Data are mean ± S.E.M.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 81 references

Research works printed but not linked: 1

  1. Sitte, H., and Bonisch, H. (2016). High-speed chronoamperometry to measure biogenic amine release and uptake in vivo. Neurotransmitter Transporters–Investigate Methods, Humana Press.

Cited by

See all 33

Metadata

Authors
Bowman, M. A., Vitela, M., Clarke, K. M., Koek, W., & Daws, L. C.
Affiliations
The University of Texas at San Antonio Health Science Center (US)
Corresponding author
Daws, Lynette C.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-10-14
Volume
21
Issue
20
Pages
7581
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3092969389
Cited by
33
References
79
Citations by year
2026: 3 · 2025: 4 · 2024: 5 · 2023: 3 · 2022: 7 · 2021: 10 · 2020: 1
FWCI
3.15
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Institutes of Health (R01MH093320, R01MH106978)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
ketamine, antidepressant mechanism, serotonin transporter, plasma membrane monoamine transporter, serotonin clearance, extracellular serotonin, major depressive disorder, NMDA receptor antagonists, hippocampal CA3, forced swim test
MeSH terms
Animals, Antidepressive Agents, Ketamine, Male, Mice, Inbred C57BL, Nucleus Accumbens, Serotonin, Equilibrative Nucleoside Transport Proteins, Serotonin Plasma Membrane Transport Proteins, Mice, CA3 Region, Hippocampal

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Serotonin Transporter and Plasma Membrane Monoamine Transporter Are Necessary for the Antidepressant-Like Effects of Ketamine in Mice. https://app.cochat.ai/papers/10.3390/ijms21207581
The paper
Bowman, M. A., Vitela, M., Clarke, K. M., Koek, W., & Daws, L. C. (2020). Serotonin Transporter and Plasma Membrane Monoamine Transporter Are Necessary for the Antidepressant-Like Effects of Ketamine in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21207581

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.